BioCentury
ARTICLE | Regulation

Josh Hardy chronicles

How Chimerix, FDA grappled with providing compassionate access to Josh Hardy

March 31, 2014 7:00 AM UTC

The Josh Hardy story puts a human face on both the lifesaving potential of compassionate use programs and the wrenching decisions company executives must make about who receives access to compounds in clinical development.

The Hardy family's social media campaign to gain access to an experimental therapy has apparently saved the seven-year-old boy's life...